# Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer

> **NCT00003327** · PHASE2 · UNKNOWN · sponsor: **Theradex** · enrollment: 60 (estimated)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT00003327
- **Lead sponsor:** Theradex
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1997-09
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2008-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003327, "Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00003327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*